Spondyloarthritis & psoriatic arthritis
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
Authors' conclusion
BKZ resulted in sustained improvements in peripheral manifestations to 2 years across the full disease spectrum of axSpA.
Study context
- Population
- Patients with non-radiographic axial spondyloarthritis (nr-axSpA) or r-axSpA with baseline enthesitis (Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)>0) or arthritis (swollen joint count (SJC)>0)
- Participants
- 254 vs 332
- Comparison
- Bimekizumab 160 mg every 4 weeks in nr-axSpA and r-axSpA
- nr-axSpAn = 254
- r-axSpAn = 332
- Primary endpoint
- Change in enthesitis (MASES) and peripheral arthritis (SJC/DAPSA); resolution of enthesitis (MASES=0)/arthritis (SJC=0)
- Follow-up
- Week 104
Methodological details16-week double-blind, placebo-controlled period, pooled bimekizumab (BKZ)/placebo-randomised
- 16-week double-blind, placebo-controlled period
- Pooled BKZ/placebo-randomised
Primary result
As reported in the abstract
Mean MASES in patients with enthesitis · baseline / week 52 / week 104
| Group | Value | Week 52 | Week 104 |
|---|---|---|---|
| nr-axSpA | average 4.8 | 1.6 | 1.6 |
| r-axSpA | average 4.3 | 1.3 | 1.0 |
Value
nr-axSpAaverage 4.8
r-axSpAaverage 4.3
Week 52
nr-axSpA1.6
r-axSpA1.3
Week 104
nr-axSpA1.6
r-axSpA1.0
- Resolution of enthesitis (MASES=0) at week 104
- Over 40%
- Resolution of arthritis (SJC=0) at week 104
- 60%
Further findings
Baseline enthesitis (MASES>0) and arthritis (SJC>0) · events/value = enthesitis
Arthritis nr-axSpA 88/254 (34.6%) · r-axSpA 66/332 (19.9%)
| Outcome | nr-axSpA | r-axSpA |
|---|---|---|
| Mean SJC in patients with arthritis · baseline / week 52 / week 104Baseline values shown as value · average | 4.0 | 4.5 |
| Week 52 | 1.2 | 0.7 |
| Week 104 | 0.9 | 0.6 |
DAPSA low disease activity/remission · week 52
- Patients achieving DAPSA low disease activity/remission
- Over 60%
Enthesitis resolution and week 104 clinical outcomes
- Enthesitis resolution associated with larger improvements in week 104 clinical outcomes in r-axSpA
Original publication
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis. RMD Open. Published 22 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →